LY3300054 + Ramucirumab + Abemaciclib + Merestinib + LY3321367
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Tumor
Conditions
Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors, Cutaneous Melanoma, Pancreatic Cancer, Breast Cancer (HR+HER2-)
Trial Timeline
Jun 29, 2016 → Jun 27, 2024
NCT ID
NCT02791334About LY3300054 + Ramucirumab + Abemaciclib + Merestinib + LY3321367
LY3300054 + Ramucirumab + Abemaciclib + Merestinib + LY3321367 is a phase 1 stage product being developed by Eli Lilly for Solid Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT02791334. Target conditions include Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors, Cutaneous Melanoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02791334 | Phase 1 | Completed |
Competing Products
20 competing products in Solid Tumor